An observational study in Pulmonary Artery Stenosis, sponsored by Cordis US Corp.. Recruiting at 8 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Cordis US Corp. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the clinical investigation is to characterize clinical outcomes and to assess the real-world use of the commercial PALMAZ MULLINS XD™ Pulmonary Stent.
The clinical study is a prospective, single-arm, multi-center, post-approval study of all consecutive subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent. The study will enroll a minimum of 35 subjects and a maximum of 75 subjects in up to 11 U.S sites or until the end of the 2-year enrollment period has been reached, whichever comes first.
The study will collect the performance and safety data of the PALMAZ MULLINS XD™ Pulmonary Stent through time of hospital discharge.
Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 2, 2026. See what changed
Subjects with pulmonary artery stenosis who are candidates for treatment with the PALMAZ MULLINS XD™ Pulmonary Stent according to clinical guidelines and/or the operators' judgement will be eligible for enrollment in this study.
- Subjects *should* meet criteria as per the list of indications/ in the Instructions for Use, though all subjects treated with the PALMAZ MULLINS XD™ Pulmonary Stent will be considered eligible and enrolled.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled subjects are treated with the PALMAZ MULLINS XD™ Pulmonary Stent
Device: PALMAZ MULLINS XD™ Pulmonary Stent
The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.
Technical Success (Successful use of the study device without additional, unplanned device or procedure-related surgery/re-intervention)
1. Successful access, delivery and retrieval of the device delivery system, 2. Deployment and correct positioning of the device in the intended location, and 3. No need for additional, unplanned surgery or re-intervention related to the device or access procedure.
Time frame: Start time of index procedure through time of discharge/study completion, usually within ~48 hours from end time of index procedure
Patency (Angiographically-determined increase in stented vessel minimum pulmonary artery diameter by ≥ 50% of the pre-stent diameter)
Increase in stented vessel minimum pulmonary artery diameter by ≥ 50% of the pre-stent diameter determined by post-implant angiography.
Time frame: Index procedure (start time to end time)
Safety Outcome (Incidence of Treatment-Emergent Serious Adverse Events)
Device or procedure-related, serious adverse events reported through time of hospital discharge, which meet any of the following criteria: 1. Led to a death, 2. Led to a serious deterioration in health of the subject, that either resulted in 1. Life-threatening illness or injury, or 2. Hospitalization (initial or prolonged) or 3. Disability or permanent impairment of a body structure or a body function or 4. Medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function 3. Other Serious (important) Medical Events
Time frame: Time of enrollment (device implant during index procedure) through time of discharge/study completion, usually within ~48 hours from end time of index procedure
Baseline Characteristics - Demographics
Demographics (age, gender)
Time frame: Pre-procedure baseline
Baseline Characteristics - Medical History
Medical History (diagnosis, prior surgery)
Time frame: Pre-procedure baseline
Baseline Characteristics - Clinical History: Weight
Clinical History (weight in kg)
Time frame: Pre-procedure baseline
Baseline Characteristics - Clinical History: Height
Clinical History (height in cm)
Time frame: Pre-procedure baseline
Baseline Characteristics - Clinical History: Body Surface Area
Clinical History (body surface area in square meters)
Time frame: Pre-procedure baseline
Target Vessel Characteristics (Stenosis type and location, lesion length and target vessel diameters)
Stenosis type and location, lesion length and target vessel diameters
Time frame: Angiography during index procedure
Procedural Characteristics (occurrence and outcomes of pre-dilation, stent deployment and post-dilation during index procedure)
Occurrence and outcomes of pre-dilation, stent deployment and post-dilation during index procedure
Time frame: Index procedure
Device Characteristics - Dimensions of PALMAZ MULLINS XD™ Pulmonary Stent
PALMAZ MULLINS XD™ Pulmonary Stent dimensions
Time frame: Index procedure
Device Characteristics - Balloon Manufacturer/Model and Dimensions
Balloon manufacturer/model and dimensions
Time frame: Index procedure
Device Characteristics - Sheath Manufacturer/Model and Dimensions
Sheath manufacturer/model and dimensions
Time frame: Index procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Dec 2025 → Jun 2026, primary completion Dec 2027 → Jun 2028 and completion Dec 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stenosis, Pulmonary Artery